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induced clinical improvement in almost all patients, those 
with advanced RA remained with signs of inflammation. 
Our report demonstrates that both the extent of systemic 
immune abnormalities and their restoration are dependent 
on duration of the active RA.
Keywords Rheumatoid arthritis · Th1/Th17/Treg 
imbalance · Cytokines · MTX · TNF inhibitors
Introduction
Rheumatoid arthritis (RA) is one of the most common sys-
temic autoimmune diseases. It is characterized by chronic 
inflammation in the synovium, resulting in progressive 
destruction of joints and cartilage. The persistent nature of 
arthritis strongly suggests immune dysfunctions associated 
with predominance of the pro-inflammatory responses. It 
seems that both local and systemic immune abnormalities 
may be involved in the disease development and evolu-
tion. Helper T cells (Th cells) play a major role in initiation 
and maintenance of the chronic inflammation in RA [1]. 
According to the cytokine microenvironment, CD4 T cells 
differentiate toward various pro- and anti-inflammatory 
subpopulations, including Th1, Th2, Th17, and T regula-
tory (Treg) cells, playing important roles in the pathogen-
esis of RA [2].
It has been shown that active RA results from an imbal-
ance in the distribution of pro-inflammatory Th17 and anti-
inflammatory Treg cells, which emphasizes the crucial roles 
of these cells in controlling RA [3]. Th1/Th17/Treg subsets 
can act as important participants of the complex network 
of interactions that manage the development and progres-
sion of RA, and, what is more important, they can exhibit 
this action at different stages of the disease with different 
Abstract Systemic immune defects might reflect severely 
dysregulated control of chronic inflammation related to 
disease progression. Th17/Treg cell imbalance has been 
demonstrated to be involved in rheumatoid arthritis (RA) 
pathogenesis. Despite controversial results, a growing anti-
inflammatory role in this process has been recently attrib-
uted to Th1 responses. The aim of the study was to estimate 
the extent of Th1/Th17/Treg imbalance in peripheral blood 
(PB) of patients with short- and long-term RA in rela-
tion to cytokine milieu and its reversal after therapy with 
methotrexate and/or TNF inhibitors, respectively. Patients 
with different duration of RA (median 6 vs. 120 months) in 
the active phase of RA were enrolled in this study. We per-
formed flow cytometric analysis of PB Th1, Th17, and Treg 
populations together with estimation of serum cytokine 
concentrations using cytometric bead array. Disease activ-
ity was calculated on the basis of clinical and biochemical 
indices of inflammation (DAS28, ESR, CRP). All param-
eters were measured and correlated with each other before 
and after 6 months therapy. Elevated levels of circulating 
Th17 cells and IL-6 were found in all active patients, of 
which Th17 cells were down-regulated by the treatment. 
Significantly reduced Th1 and functional CTLA-4+ Treg 
cell frequencies as well as Th1 cytokines observed only in 
progressive RA seemed to be irreversible. Although therapy 
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intensities. Recent data have suggested interferon-gamma 
(IFN-γ) and/or interleukin-2 (IL-2) to be protective rather 
than pro-inflammatory cytokines that could be involved in 
the down-regulation of RA-related chronic inflammation 
[4, 5]. In light of the controversial results, the exact impact 
of Th1 cell responses on Th17/Treg cell systemic distribu-
tion in RA remains uncertain [6].
Therefore, we performed a comparative analysis of 
Th1/Th17/Treg cell distribution in relation to cytokine 
milieu in peripheral blood (PB) of patients divided into 
two groups with regard to RA duration (early and advanced 
stages of RA). Then, we evaluated modifications of stud-
ied parameters after 6 months of therapy with methotrex-
ate (MTX) and/or tumor necrosis factor inhibitors (iTNF). 
We also correlated the results with clinical and laboratory 
markers of inflammation (DAS28, CRP, ESR) at each time 




The study was approved by the Ethics Committee at Wro-
claw Medical University, Poland. Written informed consent 
was obtained from each patient and healthy donor after a 
full explanation of the procedure, according to the Declara-
tion of Helsinki.
Patients
The main characteristics of RA patients are summarized 
in Table 1. Forty-four patients with RA fulfilling the 1987 
diagnostic criteria of the American Rheumatism Associa-
tion (ARA) [7] and 13 healthy volunteers were included in 
the study. Eight patients were excluded from the analysis 
due to irregular reporting to follow up visits and incom-
plete data regarding activity of the disease and adverse 
effects. In the final study, 19 patients received oral MTX 
at a dose of 15 mg per week (MTX group); median (inter-
quartile range) RA duration was 6 months (3–16 months). 
The other 17 were treated with recommended doses of 
TNF-α inhibitors (infliximab (n = 11), adalimumab 
(n = 2), or etanercept (n = 4) (iTNF group); median RA 
duration was 120 months (60–160 months). One of the 
inclusion criteria was active form of the disease estab-
lished on the basis of clinical and biochemical indices 
of inflammation, such as the erythrocyte sedimentation 
rate (ESR), C-reactive protein (CRP), and calculation of 
the disease activity score (DAS28); for MTX treatment 
DAS28 > 3.2, and for iTNF administration DAS28 > 5.1. 
Based on the statistically significant differences in the 
median active disease duration and DAS28 score either 
before or after the treatment between the two groups, 
iTNF patients were assigned to the progressive form of 
the disease.
For biologics to be used, treatment failure with at least 
two traditional disease-modifying antirheumatic drugs 
(DMARDs) including MTX was required. Thus, all iTNF 
patients had received MTX in the past history; 13 out of 
17 patients were still receiving MTX when iTNF therapy 
was started. Because of the disease activity, patients were 
allowed to continue treatment with DMARDs, including 
MTX, sulphasalazine, glucocorticoids, and nonsteroidal 
anti-inflammatory drugs, if the treatment regimens were 
not modified 4 weeks before the study. Based on the effi-
cacy of the therapy, the clinical improvement of RA was 
established according to the response criteria suggested 
by the European League Against Rheumatism (EULAR), 
if reduction of DAS28 was >0.6 (moderate efficacy) or 
even >1.2 (good efficacy)[8]. Accordingly, at least par-
tial improvement was achieved in 14 (82.35 %) and 19 
(100 %) patients treated with iTNF and MTX, respec-
tively. Blood samples were collected just before and 
after 6 months of the therapy. Healthy individuals were 
free of the following events: inflammatory syndrome 
(CRP < 0.5 mg/dL), steroid or immunosuppressive ther-
apy, acute or chronic infectious diseases, other autoim-
mune diseases, and cancers. The controls were matched 
with patients for age and sex.
Cell preparation, culture conditions, and flow cytometry
Peripheral blood mononuclear cells (PBMCs) were iso-
lated by buoyant density-gradient centrifugation on 
Lymphoflot (Biotest, Germany) from 40 ml of freshly 
drawn peripheral venous blood (PB). Because incuba-
tion with phorbol 12-myristate 23-acetate (PMA) triggers 
internalization and degradation of the CD4 molecule, 
which would affect the identification of Th1 (CD4+IL-
17-IFN-γ+) and Th17 (CD4+IFN-γ-IL-17+) cells [9], 
CD4+ T cells were negatively separated before cytokine 
staining. CD4+ T cells purified by magnetic cell sorting 
(Miltenyi Biotec) were then stimulated with 25 ng/ml 
PMA and 1 μg/ml of ionomycin (Ion) (Sigma-Aldrich) 
in the presence of 10 μg/ml of brefeldin A (BFA, pro-
tein transport inhibitor) for 4 h at 37 °C in a humidified 
atmosphere containing 5 % CO2. For analysis of Tregs 
(CD4+FoxP3+ T cells) as well as CTLA-4+Tregs, 
PBMCs were aliquoted into tubes directly after isola-
tion for further staining performed as follows: the cells 
were stained with anti-CD3/FITC (clone UCHT1; BD 
Pharmingen), anti-CD4/PerCP (clone SK3; BD Pharmin-
gen) or anti-CD4/FITC (clone SK3; BD Pharmingen), 
and CTLA-4/PE-Cy monoclonal antibodies (mAbs) 
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(clone BNI3; BD Pharmingen). For intracellular stain-
ing, the cells were fixed and permeabilized with BD 
Permeabilizing Solution 2 (Becton–Dickinson) accord-
ing to the manufacturer’s instructions with subsequent 
incubation with anti-IFN-γ/FITC (clone 25723.11; BD 
Pharmingen), anti-IL-17/PE (clone eBio64DEC17; eBio-
science), anti-human FoxP3/PE mAbs (clone 259D/C7; 
BD Pharmingen), or fluorochrome-labeled isotypic con-
trol mAbs for 30 min at room temperature in the dark. 
Directly after immunostaining, the cells were washed and 
analyzed by flow cytometry using a FACScan cytometer 
equipped with Cell Quest software (BD Bioscience).
RNA isolation and real-time PCR (RT-PCR)
Total RNA was extracted from CD4+ T cells using RNeasy 
columns (Qiagen, Hilden, Germany), subjected to DNase 
I treatment according to the manufacturer’s protocols 
and immediately 800 ng of RNA was reverse transcribed 
using the iScript cDNA Synthesis Kit (Biorad, Hercules, 
CA, USA). The mRNA levels of human IL-17A, FoxP3, 
INFγ, and β2 microglobulin (β2M) were analyzed by 
quantitative real-time PCR using primers and probes from 
Applied Biosystems (Hs00174383_m10, Hs01085832_m1, 
Hs00989291_m1, and Human β2M, respectively). All the 
samples were analyzed using the 7300 Real-Time Instru-
ment (Applied Biosystems). To calculate relative expres-
sion, all results were analyzed according to the ΔCt method 
using β2M as a reference gene.
Cytokine assays
Cytokines (IL-6, IL-2, IFN-γ, TNF-α, and IL-17) were 
measured in patients’ and controls’ sera by a flow cyto-
metric bead array using human cytokines kits of the BD™ 
CBA Human Soluble Protein Flex Set system (Becton–
Dickinson) and analyzed on a FACSCalibur flow cytometer 
(Becton–Dickinson), as recently described [10].
Statistical analysis
One-way ANOVA test was used to determine significant 
differences between groups. Spearman’s test was used for 
correlation analysis. The Wilcoxon signed rank test was 
used to compare paired patients before and after the treat-
ment. Results were considered statistically significant when 
P ≤ 0.05. Data are presented as median (interquartile range). 
Statistica’99 Edition was used in the statistical calculations.
Results
Pre-treatment distribution of PB Th1, Th17, and Treg cell 
population
In order to determine the relationship between the duration 
of active RA and distribution of anti- and pro-inflammatory 
Th cell subpopulations in PB, we assessed the proportion 
of Th1, Th17, and Treg cells in patients before MTX and/
or iTNF administration. We did not find any significant dif-
ferences in the relative mRNA expression of IFN-γ, IL-17, 
and FoxP3 between all studied groups (Table 2). Both 
groups of RA patients exhibited significantly and similarly 
increased Th17 populations compared to controls (Figs. 1a, 
2b). Only iTNF patients possessed a reduced Th1 cell pop-
ulation compared to others. There were no differences in 
Th1 cell frequency in PB between MTX patients and con-
trols (Figs. 1a, 2a). The proportions of circulating Treg 
cells as well as those co-expressing the suppressor CTLA-4 
molecule (CTLA-4+ Tregs) were lower in the iTNF group 
than in controls, in contrast to the similar values in the 
MTX group and healthy subjects (Figs. 1b, c, 2c, d).
Pre-treatment serum cytokine profile
We also verified whether the different duration of active 
RA might modify the serum cytokine profile, thus affecting 
Table 2  IFN-γ, Foxp3, 
and IL-17 mRNA relative 
expression in PB CD4+ T cells 
of RA patients and normal 
controls; the median levels of 
mRNA [interquartile range]
* P = 0.048, ** P = 0.007, 
*** P = 0.01  compared to the 
iTNF group after therapy
IFN mRNA Foxp3 mRNA IL-17 mRNA
MTX group
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CD4 Th cell differentiation. All RA patients showed higher 
serum concentrations of IL-6 than controls, with the highest 
values in the iTNF group (Fig. 3a). Solely the iTNF group 
possessed lower levels of Th1 cytokines, more pronounced 
considering IL-2 (Fig. 3b, c). In contrast, no differences in 
Th1 cytokine values between MTX patients and controls 
Fig. 1  Representative examples of flow cytometric analyses of Th1, 
Th17, Treg, and functional CTLA-4+ Treg cell populations in active 
RA patients and controls. a Th1 (CD4+IL-17-IFN-γ+) and Th17 
(CD4+IFN-γ-IL-17+) cells in studied groups presented as dot plots. 
b Expression of FoxP3 transcription factor in total CD4+ T cells in 
the studied groups presented as open histograms. c Expression of 
CTLA-4 suppressive molecule in total CD4+FoxP3+ T cells in the 
studied groups presented as open histograms. Grey histograms repre-
sent isotype controls
Fig. 2  Frequencies of circulating Th1, Th17, Treg, and CTLA-4+ 
Treg cells and DAS28 in RA patients before and after therapy com-
pared to healthy controls. a Th1 (CD4+IL-17-IFN-γ+) cells. b Th17 
(CD4+IFN-γ-IL-17+) cells. c Treg (CD3+CD4+Foxp3+) cells. 
d Functional Treg (CD4+Foxp3+CTLA-4+) cells. e Modification 
of the DAS28. Whiskers are as follows: median (horizontal bar), IQ 
range (box), and extreme values (error bars)
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were seen (Fig. 3b, c). Serum TNF-α and IL-17 reached 
similar levels in all patients and controls (Fig. 3d, e).
Post-treatment distribution of PB Th1, Th17, and Treg cell 
population
Next, we tried to explore the relevance of therapy in the 
studied subpopulations depending on RA duration. A 
decrease in the PB Th17 cell population after the treat-
ment in all patients, but more vigorous in MTX patients, 
was found (Fig. 2b). Nevertheless, the iTNF treatment 
up-regulated IL-17 gene activity, resulting in higher 
relative expression of IL-17 mRNA in CD4+ T cells of 
iTNF patients compared to the MTX group and to con-
trols (Table 2). Accordingly, Th17 cells were expanded to 
twofold higher levels in PB of patients compared to con-
trols; however, the differences were not statistically sig-
nificant (Fig. 2b). Although the levels of relative mRNA 
expression of both IFN-γ and FoxP3 did not differ mark-
edly between studied groups (Table 2), the iTNF patients 
maintained a systemic Th1 cell loss after the treatment 
(Fig. 2a). In contrast, MTX patients demonstrated a simi-
lar Th1 cell population compared to controls (Fig. 2a). 
Therapy changed, albeit nonsignificantly, the frequency 
of PB Treg cells in all RA patients, reversing, in conse-
quence, defective Treg proportions in the iTNF group 
(Fig. 2c). Nevertheless, Tregs from these patients main-
tained CTLA-4 expression in the diminished proportions 
of cells compared to healthy corresponding Treg cells 
(Fig. 2d).
Post-treatment serum cytokine profile
We assessed serum cytokine modification under the differ-
ent therapeutic interventions regarding RA duration as well. 
A decline of serum IL-6 concentrations was seen only in the 
MTX group. Nevertheless, its level was not normalized in all 
patients (Fig. 3a). Among the patients, IL-6 concentration 
was highest in the iTNF group. IL-2 and IFN-γ remained 
at lower concentrations in sera from iTNF patients (Fig. 3b, 
c). In contrast, increased IL-2 levels were found only in the 
MTX group (Fig. 3b). Neither MTX nor iTNF treatment 
changed TNF-α or IL-17 concentrations in RA, their levels 
being comparable to those seen in controls (Fig. 3d, e).
Correlation between clinical, immune, and laboratory 
parameters in patients at different stages of RA
We analyzed correlations among the proportion of exam-
ined T helper subpopulations (Th1, Th17, and Treg) in PB, 
serum soluble factors (IL-6, IL-2, IFN-γ, TNF, and IL-17), 
and clinical and/or laboratory features of RA in all studied 
groups of patients before and after the treatment. We found 
several statistically significant relationships among stud-
ied parameters, of which the most interesting comparisons 
have been presented in Table 3.
Fig. 3  Serum cytokine concentrations in RA patients before and after the treatment compared to healthy controls. The median levels of 
cytokines. a IL-6. b IL-2. c IFN-γ. d TNF-α. e IL-17. Error bars are the IQ range
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Discussion
Our present work strongly demonstrates that RA patients 
present an imbalance in CD4 T cell subsets’ distribution 
in PB, more pronounced in those with the most advanced 
disease, suggesting the impact of disease progression on 
subsequent changes. Considering CD4 T cell subpopula-
tions, a common disorder found in all RA patients irre-
spective of the disease duration was expansion of Th17 
cells in circulation. This observation is in accordance 
with previous reports [11–20] and confirms that Th17 
is a key effector cell in the pathogenesis of RA [21]. Its 
strong pro-inflammatory action has been attributed to 
secretion of IL-17 and, to a lesser extent, TNF-α and IL-6 
[22]. In addition, IL-17 induces the production of TNF-α, 
IL-6, and IL-1beta in numerous cell types [23] and can 
act in synergy with TNF-α to stimulate the production of 
pro-inflammatory cytokines, chemokines and metallopro-
teases from synovial fibroblasts, leading finally to carti-
lage loss [24, 25]. Moreover, during the course of RA it 
can promote osteoclastogenesis and bone absorption [26]. 
On the other hand, Th17 differentiation is dependent on 
IL-6 abundantly expressed in the inflamed joints and PB 
in patients with active RA, which emphasizes their recip-
rocal regulation [27, 28]. Permanently augmented concen-
trations of IL-6 in sera from RA patients [29] have been 
also confirmed in our study even after the biologic treat-
ment. Consequently, we observed significantly enhanced 
activity of the IL-17 gene in the same patients. It should 
be stressed, however, that only patients with relatively 
short duration of active RA exhibited a higher potential 
for reversion of dysregulated IL-6 and Th17 cells as well 
as for reduction in disease activity compared to those with 
advanced disease.
Table 3  Correlations between 
clinical, immune, and laboratory 
parameters in RA patients
NS nonsignificant
Correlated parameters MTX treatment iTNF treatment
Before After Before After








IL-6/Th1 NS NS P = 0.05
r = −0.45
NS
IL-6/Th17 NS NS P = 0.04
r = 0.66
NS
IL-6/DAS28 NS NS NS P = 0.02
r = 0.54
Th1/DAS28 NS NS P = 0.03
r = −0.50
NS








Th1/Treg NS NS NS P = 0.05
r = 0.45
IL-2/CRP NS P = 0.007
r = −0.92
NS NS
IL-2/CTLA-4+Treg NS NS P = 0.02
r = 0.71
NS
Treg/CRP NS NS P = 0.002
r = −0.87
NS
CTLA-4+Treg/CRP NS NS NS P = 0.02
r = −0.64
Th17/Treg NS NS P = 0.05
r = −0.65
NS
CTLA-4+Treg/Th17 P = 0.01
r = − 0.61
P = 0.05
r = − 0.45
NS P = 0.04
r = −0.44
TNF/Treg NS NS P = 0.05
r = −0.65
NS








IL-2/IFN NS NS NS P = 0.05
r = 0.62
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Of note, no significant changes were observed in the 
serum levels of TNF-α and IL-17 in all patients at each 
time point tested, which was an unexpected observation 
when we consider their strong pro-inflammatory action 
and fundamental role in RA development [30]. Previous 
assessments demonstrated no significant increment [13, 
14, 31] or, alternatively, an increase in TNF-α or IL-17 in 
sera from RA patients [11, 12, 30, 32–35]. It seems rea-
sonable that unstable in vitro activity of TNF-α and IL-17 
probably resulting from the relatively short half-life of both 
cytokines might affect their detectable levels found in our 
experiments [35]. Since IL-6 has a much longer half-time 
and is closely and positively interrelated with TNF-α and 
IL-17 in all studied patients, it appears to reflect intrinsic 
concentrations of both factors, thus being a better disease 
marker for measurements in patients’ sera [35].
It should be emphasized that progression of RA seems 
to correspond with many additional alterations in systemic 
distribution of T helper subsets studied, as was recently 
suggested [36]. In particular, we demonstrated that during 
disease evolution PB Th17 expansion was accompanied 
by diminished Th1 and Treg cell populations, indicating a 
profound imbalance in pro- and anti-inflammatory T cells 
in the periphery. We found that changes in the intracellular 
expression of IFN-γ, IL-17, and FoxP3 transcription fac-
tor seen in PB CD4+ T cells from untreated RA patients 
might be due to the post-transcriptional alterations rather 
than the markedly disturbed gene activity. Recently, other 
investigators have reported dysregulated Treg numbers in 
the periphery in active RA. Some studies demonstrated 
decreased [37], unchanged [38], or increased percentages 
of peripheral Tregs in the course of RA [39]. All these 
discrepancies may result from the differences in determi-
nation of Treg unique phenotype. Furthermore, since the 
CTLA-4 molecule plays a crucial role in Treg function, our 
study showing decreased CTLA-4+ Treg frequency in PB 
in advanced RA points to the possibility of Treg functional 
impairment especially during disease progression [38, 40]. 
However, the overall reasoning has to be cautious due to 
the lack of Treg functional assay in our experiment.
The current study clearly showing a systemic loss of 
Th1 cell population in progressive RA corresponds with 
some recent observations on a relation of RA activity/pro-
gression with Th1 defective response in PB [41, 42]. How-
ever, several previous reports showed contradictory results; 
some of them described increased [15, 35] or unchanged 
frequencies of Th1 cells in circulation in the course of RA 
[43, 44]. These discrepancies may be related to the fact that 
examined patients exhibiting a systemic decrement of Th1 
cell frequency had much longer duration of the active dis-
ease, which may indicate the impact of RA progression on 
Th1 lineage restriction. In contrast, patients with relatively 
short-term disease assigned to MTX therapy exhibited no 
changes in the numbers of PB Th1 cells, which was con-
sistent with past studies [43, 44].
Mechanisms underlying the decreased proportion of 
peripheral Th1 cells in advanced RA are not fully under-
stood, but the influence of the serum cytokine profile 
affecting CD4 Th cell differentiation should have been 
taken into account. Since we found that the levels of 
cytokines exerting inhibitory activity toward Th1 differ-
entiation, including IL-6 and IL-17 [45, 46], did not differ 
significantly between examined groups of patients, it seems 
that other factors may affect the Th1 lineage in progres-
sive RA rather than dysregulated differentiation. In fact, 
a few previous reports suggested selective migration of 
Th1 cells from PB into inflamed joints in active RA [41, 
47, 48], which might result in altered Th1 frequencies in 
PB. It cannot be excluded that the strength of this process 
corresponds with disease activity/severity, since we found 
that solely the iTNF group of patients remained with a 
systemic Th1 defect inversely correlated, in addition, with 
stably increased CRP levels even after the therapy. Another 
explanation for PB Th1 cell down-regulation in progres-
sive RA is the possible impact of long-term use of some 
drugs capable of interfering with the Th1 phenotype, such 
as MTX, iTNF, and/or statins [49–51]. It is, however, dif-
ficult to distinguish between the role of pharmacological 
treatment per se and the severity/duration of RA in decre-
ment of Th1 cell percentages as both parameters seem to be 
closely interrelated.
Consequently, the lower proportion of circulating Th1 
cells was accompanied by diminished serum levels of Th1 
cytokines, including IL-2 and IFN-γ. In fact, qualitative 
impairment of PB effector T cells, especially those with 
Th1 phenotype, was attributed to chronic exposure to 
stimulation via TNF-α [52]. Consistently with us, a deficit 
in serum Th1 cytokines in active RA and/or their negative 
relationship with disease activity have also been reported 
[34, 35, 41, 42, 53]. It is worthy of note, however, that 
our results contradict several previous reports show-
ing increased or unchanged circulating Th1 cytokines in 
RA [12, 32, 33, 35] only in the part considering patients 
with the most advanced disease. Furthermore, in the 
same group of patients, we did not observe any influence 
of long-term iTNF treatment on changes in PB Th1 cell 
responses, as they entered the study with compromised 
baseline Th1 cytokine values. In some experiments, 
involving patients with relatively early stages of RA with 
no Th1 defects, a down-regulating effect of iTNF was 
observed [15, 50].
Given that IL-2 was demonstrated to be critical for the 
differentiation of Tregs from naïve CD4+ T cells, the lack 
of significant difference in Treg frequency between the 
MTX group and iTNF group despite evident decrease in 
serum IL-2 levels in the latter was, in fact, an unexpected 
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finding. Nevertheless, it seems to be consistent with the 
recent studies showing an important role of IL-2 in the 
maintenance of homeostasis of the circulating Treg cell 
compartment [54], consisting of both the natural CD62Lhi 
and induced CD62Llo FoxP3+Tregs [55]. It has been 
shown that natural Tregs are more sensitive to changes in 
the level of IL-2 than induced Treg cells [56]. In particu-
lar, Goudy et al. [56] demonstrated that IL-2 shortage could 
correlate with a decreased proliferative status of natu-
ral Tregs in a mice model of autoimmunity, but not with 
induced Tregs, despite similar levels of CD25 and CTLA-4 
surface expression between the arms. Therefore, an obvi-
ously reduced expression of serum IL-2 found in iTNF 
patients with progressive disease might dysregulate the 
ratio of the CD62Lhi to CD62Llo Tregs, which exert differ-
ent suppressive potential, thus resulting in qualitative rather 
than quantitative differences in the FoxP3+ Treg pool 
detected in their circulation.
In addition to the generation and survival of Treg cells, 
inhibition of Th17 polarization appears to be an important 
function of IL-2; hence this Th1 cytokine is capable of 
controlling the Th17/Treg balance in the periphery [5, 57, 
58]. In fact, an affected Th1 response has been suggested 
to shift the T cell homeostasis from a Treg-mediated toler-
ant state to Th17-mediated active inflammatory conditions 
[4, 57]. An increase in inflammatory disease activity in the 
presence of impaired Th1 responses has been well docu-
mented [6, 59–61]. Therefore, an increased Th17/Treg 
ratio in PB of the most advanced RA patients examined, 
which corresponded with either down-regulation of Th1 
cells or laboratory signs of inflammation strengthens 
the suggestion that those systemic alterations may be, 
in fact, an immune signature of disease progression. In 
this context, we observed a Th1 protective response only 
in patients with short-term RA. Additional correlations 
among studied subpopulations and markers of inflamma-
tion seen in advanced RA emphasize a major role of sys-
temic Th1 alterations in the management of Th17/Treg 
imbalance at this stage of the disease.
Herein, we also demonstrated that the main immune 
advantage of the therapy with MTX and/or iTNF in exam-
ined RA patients was the reversion of Th17 cell expan-
sion. Available data concerning the effect of the different 
therapeutic interventions on the Th17 cell population are 
still confusing. Several studies have shown an unchanged 
[13, 15, 20] or, alternatively, a decreased Th17 frequency 
following treatment with MTX and/or iTNF [13–16, 19, 
20], and the latter findings are in accordance with the cur-
rent study. Similarly to the recent work [20], monotherapy 
with MTX was able to effectively limit the Th17 popu-
lation only in the patients with early disease. In general, 
our study showed that the treatment used exhibited the 
most beneficial effect mainly for patients at a relatively 
early stage of the disease, as Th17 expansion was the 
only Th cell alteration seen in those patients’ circulation. 
As regards the patients with progressive disease, they 
required biologic treatment to be used. All the reports 
consistent with ours [13–16, 19, 20] strengthen the con-
clusion that the effectiveness of iTNF therapy concern-
ing Th17 expansion should be evaluated not earlier than 
12 weeks after biologics usage irrespective of the MTX 
administration.
Although the therapy with iTNF partially corrected 
the Th17/Treg imbalance seen in the most advanced RA, 
which was in line with other reports [15], it was accom-
plished also due to affecting the Th17 population, but not 
by evident Treg frequency improvement. Nonetheless, sys-
temic Th1 loss and compromised Treg function, as evalu-
ated by sustained lower PB Th1 and CTLA-4+ Treg fre-
quency in the iTNF group despite the treatment, seemed 
to be irreversible phenomena in progressive disease. 
Although restoration of Treg suppressive activity after 
iTNF therapy has been previously reported, this improve-
ment was only transient or restricted to the patients 
responding to the treatment [38]. We suggest that the com-
promised influence of iTNF on the proportion of func-
tional CTLA-4+ Tregs in progressive RA is associated 
with an irreversible deficit in Th1 cytokine level. In par-
ticular, serum IL-2 shortage might be responsible for per-
sistent qualitative alterations within Treg pool, when we 
consider a crucial role of IL-2 either in the maintenance of 
Treg compartment homeostasis [56] or in CTLA-4 expres-
sion in T cells [62]. While it is true that CTLA-4 contrib-
utes to the suppressive function of Tregs [40], it cannot be 
used as a single marker to define the functional status of a 
Treg; hence its functional significance should be consid-
ered with caution.
In conclusion, our study shows that both the degree 
of the immune alterations in PB of RA patients and their 
reversal after different therapeutic interventions depend on 
the duration of the active disease. Patients with relatively 
short-term disease possess a higher capacity for reversion 
of the studied abnormalities. In contrast, patients with pro-
gressive and long-term RA remain with much immune 
dysregulation managed by Th1 systemic defects even 
after iTNF treatment. Therefore, patients at early stages of 
active RA would certainly benefit from iTNF administra-
tion rather than those with the most advanced disease. In 
this context, new approaches based on restoration of Th1 
protective responses capable of controlling the balance 
between Th17 and Tregs would be of interest as another 
target for the treatment of progressive RA. Recently, such 
a study concerning the influence of exogenous IL-2 on the 
balance in Th1, Th17, and Treg cell distribution in the dif-
ferent stages of RA was performed in our laboratory (data 
to be published).
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